TNDM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
283.7M
+11.4%
254.6M
+3.0%
247.2M
-14.9%
290.4M
+16.5%
249.3M
Cost of Revenue
123.3M
+12.3%
109.8M
-0.6%
110.4M
-10.2%
122.9M
+6.9%
115.0M
Gross Profit
160.4M
+10.8%
144.8M
+5.8%
136.8M
-18.3%
167.5M
+24.7%
134.3M
Operating Expenses
162.8M
+2.7%
158.6M
+2.8%
154.2M
-3.1%
159.2M
+1.3%
157.2M
R&D
48.8M
+4.1%
46.9M
+1.9%
46.0M
-0.1%
46.1M
-5.4%
48.7M
SG&A
113.9M
+2.1%
111.6M
+3.2%
108.2M
-4.3%
113.1M
+4.3%
108.4M
Operating Income
-2369000
+82.8%
-13792000
+20.9%
-17434000
-310.2%
8.3M
+136.3%
-22863000
EBITDA
2.1M
+123.0%
-9322000
+27.9%
-12930000
-201.1%
12.8M
+169.6%
-18370000
Net Income
-7085000
+66.5%
-21168000
-3.8%
-20393000
-3362.3%
-589000
+97.2%
-21165000
EPS (Basic)
$-0.10
+67.7%
$-0.31
-3.3%
$-0.30
-2900.0%
$-0.01
+96.8%
$-0.31
EPS (Diluted)
$-0.10
+67.7%
$-0.31
-3.3%
$-0.30
-2900.0%
$-0.01
+96.8%
$-0.31
Shares (Diluted)
69.7M
+0.9%
69.0M
+0.9%
68.4M
+0.5%
68.0M
+0.6%
67.7M
Tandem Diabetes Care (TNDM) — Financials